(Q36003459)

11 August 2017

1 reference

title

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

11 August 2017

0 references

1 reference

Brian J Lipworth

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

365

1 reference

11 August 2017

issue

9454

1 reference

11 August 2017

page(s)

167-175

1 reference

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Theophylline: new perspectives for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Cyclic nucleotide phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Warfarin pharmacodynamics unaffected by cilomilast

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917708-3

7 January 2021

10.1016/S0140-6736(05)17708-3

Identifiers

DOI

1 reference

11 August 2017

1 reference